Skip to main content

Table 3 Adverse events in patients who completed the two-day course of artemisinin-piperaquine (ARPQ, n = 62) and the three-day course of artesunate-amodiaquine (ASAQ, n = 63) in Vietnamese patients with Plasmodium falciparum malaria

From: The efficacy and tolerability of artemisinin-piperaquine (Artequick®) versus artesunate-amodiaquine (Coarsucam™) for the treatment of uncomplicated Plasmodium falciparum malaria in south-central Vietnam

ARPQ Before treatment 24 h after 1 st dose 24 h after 2 nd dose 48 h after 2 nd dose
Fever 88.7% (55/62) 29.0% (18/62) 1.6% (1/62) NR
Headache 87.1% (54/62) 48.4% (30/62) 1.6% (1/62) 1.6% (1/62)
Nausea 29.0% (18/62) 3.2% (2/62) NR NR
Stomach pain 1.6% (1/62) NR NR NR
Vomiting 1.6% (1/62) NR NR NR
Dizziness 27.4% (17/62) 3.2% (2/62) NR NR
Tiredness 61.3% (38/62) 25.8% (16/62) 3.2% (2/62) 1.6% (1/62)
Anorexia 43.5% (27/62) 9.7% (6/62) 1.6% (1/62) 1.6% (1/62)
ASAQ Before treatment 24 h after1 st dose 24 h after 2 nd dose 24 h after 3 rd dose
Fever 82.5% (52/63) 20.6% (13/63) 3.2% (2/63) NR
Headache 95.2% (60/63) 46.0% (29/63) 3.2% (2/63) NR
Nausea 41.3% (26/63) 19.0% (12/63) 1.6% (1/63) NR
Stomach pain NR NR NR NR
Vomiting 3.2% (2/63) 3.2% (2/63) NR NR
Dizziness 25.4% (16/63) 3.2% (2/63) NR NR
Tiredness 69.8% (44/63) 30.2% (19/63) 3.2% (2/63) NR
Anorexia 46.0% (29/63) 20.6% (13/63) NR NR